Long-acting injectable CAB+RPV maintains high virologic suppression in patients with HIV and obesity, showing comparable real-world efficacy.

The global challenge posed by HIV-1 infection continues to drive research into its underlying mechanisms and the host immune response. Central to this pursuit is the role of T cells, particularly CD4 ...

What are the three types of HIV tests available to patients, how do they differ, and how can patients determine the best option for them?

Lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, has shown 100% efficacy in preventing HIV in women at a high risk for infection, according to an interim analysis of the phase 3 PURPOSE ...

Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...

The HIV prevention shot lenacapavir will be rolled out at South African clinics within the next couple of months — from 2027, ...

HIV is preventable, yet new diagnoses continue in AZ at higher-than-average rates. Could a new, twice-yearly shot called ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.